Remove 2028 Remove Diabetes Remove Drug Development
article thumbnail

Alimera Sciences buys US rights to EyePoint’s Yutiq

Pharmaceutical Technology

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.